These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 6836988

  • 1. [Immediate results of sarcolysine therapy of patients with malignant tumors of the ovaries].
    Semenovskiĭ AV.
    Vopr Onkol; 1983; 29(3):54-7. PubMed ID: 6836988
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Chemotherapy for ovarian cancer].
    Lindell A.
    Lakartidningen; 1968 Mar 13; 65(11):1120-2. PubMed ID: 5743130
    [No Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of bleomycin in patients with advanced epithelial ovarian cancer.
    Blackledge G, Lawton F, Buckley H, Crowther D.
    Cancer Treat Rep; 1984 Mar 13; 68(3):549-50. PubMed ID: 6200221
    [Abstract] [Full Text] [Related]

  • 5. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
    Gershanovich ML, Livshits ME, Antipenkova VI.
    Vopr Onkol; 2000 Mar 13; 46(5):604-7. PubMed ID: 11202196
    [Abstract] [Full Text] [Related]

  • 6. [Tissue reaction in ovarian carcinoma after cyclophosphamide (Endoxan) therapy].
    Engeler V, Hanski W.
    Pathol Microbiol (Basel); 1969 Mar 13; 33(3):153-60. PubMed ID: 5350583
    [No Abstract] [Full Text] [Related]

  • 7. [Combined chemotherapy of ovarian cancer with special reference to carboquone].
    Sugimori H, Kidera Y, Matsuyama T.
    Gan To Kagaku Ryoho; 1982 Jan 13; 9(1):66-71. PubMed ID: 6307172
    [Abstract] [Full Text] [Related]

  • 8. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
    Dzhilavian GA, Vinokurov VL.
    Vopr Onkol; 1984 Jan 13; 30(3):16-21. PubMed ID: 6424327
    [Abstract] [Full Text] [Related]

  • 9. [Sarcolysine in the treatment of malignant ovarian tumors].
    Dzhardemov AA.
    Vopr Onkol; 1977 Jan 13; 23(12):90-2. PubMed ID: 341515
    [No Abstract] [Full Text] [Related]

  • 10. Chemotherapy of malignant ovarian tumors; therapeutic results of ifosfamide.
    Yakushiji M, Tsunawaki A, Nishida T, Nishimura H, Natsuaki Y, Inoue T, Kato T.
    Acta Obstet Gynaecol Jpn; 1981 Jul 13; 33(7):1071-6. PubMed ID: 7304132
    [Abstract] [Full Text] [Related]

  • 11. Factors influencing ovarian cancer survival after chemotherapy.
    Webb MJ, Malkasian GD, Jorgensen EO.
    Obstet Gynecol; 1974 Oct 13; 44(4):564-70. PubMed ID: 4413425
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic, clinical and histological factors related to the survival of patients with advanced ovarian carcinoma.
    Kauppila A, Kivinen S, Mäkilä UM, Järvinen PA.
    Ann Chir Gynaecol; 1981 Oct 13; 70(3):91-5. PubMed ID: 7325582
    [Abstract] [Full Text] [Related]

  • 13. [1st report on programmed chemotherapy of ovarian carcinoma].
    Frank S, Richter K, Ehrhart H, Penning W, Meister P, Schmidt D, Götz A.
    Fortschr Med; 1975 Oct 09; 93(28):1309-12. PubMed ID: 1228086
    [Abstract] [Full Text] [Related]

  • 14. Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo.
    Tropé C, Sigurdsson K.
    Neoplasma; 1982 Oct 09; 29(3):309-14. PubMed ID: 7133226
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 16. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
    Dusenbery KE, Bellairs EE, Potish RA, Twiggs LB, Boente MP.
    Gynecol Oncol; 2005 Feb 15; 96(2):307-13. PubMed ID: 15661213
    [Abstract] [Full Text] [Related]

  • 17. [Chemotherapy of patients with recurring malignant tumors of the ovaries].
    Kotova DG, Vinokurov VL.
    Vopr Onkol; 1975 Feb 15; 21(4):19-23. PubMed ID: 812259
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 19. High dose thiotepa in ovarian cancer.
    Shetty PA, Kurkure PA, Pai VR, Gohokar D, Pai S, Shinde SR, D'Souza LJ, Sampat MB.
    Indian J Cancer; 1985 Mar 01; 22(1):33-7. PubMed ID: 3939232
    [No Abstract] [Full Text] [Related]

  • 20. Chemotherapy in advanced ovarian cancer.
    Schein PS.
    Geriatrics; 1973 Dec 01; 28(12):89-95. PubMed ID: 4128004
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.